Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro M Vannucchi

Showing results (1-10 of 413) with videos related to

Pageof 42
Sort By:
Leukemia Research|July 4, 2009
How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesisAlessandro M Vannucchi
Blood|December 6, 2019
Pegasus causes inherited thrombocytopeniaAlessandro M Vannucchi
The New England Journal of Medicine|April 23, 2015
Ruxolitinib versus standard therapy for the treatment of polycythemia veraAlessandro M Vannucchi
Current Hematologic Malignancy Reports|April 29, 2010
JAK2 mutation and thrombosis in the myeloproliferative neoplasmsAlessandro M Vannucchi
Blood|October 4, 2014
How I treat polycythemia veraAlessandro M Vannucchi
The New England Journal of Medicine|September 17, 2010
From palliation to targeted therapy in myelofibrosisAlessandro M Vannucchi
Internal and Emergency Medicine|October 1, 2009
Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemiaAlessandro M Vannucchi
Hematology. American Society of Hematology. Education Program|December 14, 2011
Management of myelofibrosisAlessandro M Vannucchi
Haematologica|November 26, 2016
From leeches to personalized medicine: evolving concepts in the management of polycythemia veraAlessandro M Vannucchi
Current Opinion in Oncology|September 1, 2010
Advances in understanding and management of polycythemia veraAlessandro M Vannucchi, Paola Guglielmelli
Pageof 42

Showing results (1-10 of 413) with videos related to

Sort By:
Pageof 42
Leukemia Research|July 4, 2009
How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesisAlessandro M Vannucchi
Blood|December 6, 2019
Pegasus causes inherited thrombocytopeniaAlessandro M Vannucchi
The New England Journal of Medicine|April 23, 2015
Ruxolitinib versus standard therapy for the treatment of polycythemia veraAlessandro M Vannucchi
Current Hematologic Malignancy Reports|April 29, 2010
JAK2 mutation and thrombosis in the myeloproliferative neoplasmsAlessandro M Vannucchi
Blood|October 4, 2014
How I treat polycythemia veraAlessandro M Vannucchi
The New England Journal of Medicine|September 17, 2010
From palliation to targeted therapy in myelofibrosisAlessandro M Vannucchi
Internal and Emergency Medicine|October 1, 2009
Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemiaAlessandro M Vannucchi
Hematology. American Society of Hematology. Education Program|December 14, 2011
Management of myelofibrosisAlessandro M Vannucchi
Haematologica|November 26, 2016
From leeches to personalized medicine: evolving concepts in the management of polycythemia veraAlessandro M Vannucchi
Current Opinion in Oncology|September 1, 2010
Advances in understanding and management of polycythemia veraAlessandro M Vannucchi, Paola Guglielmelli
Pageof 42